Business Context and Reporting Period
This Form 8-K was filed by India Globalization Capital, Inc. (IGC Pharma, Inc.) on March 13, 2020. The report addresses "Other Events" (Item 8.01) concerning the operational impact of the COVID-19 outbreak and updates on the acquisition of Evolve I, Inc.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. It references a prior 10-Q filed on February 10, 2020, for historical context but does not restate those numbers here.
Financial details regarding the Evolve I, Inc. acquisition include:
- Total Consideration: Approximately $6 million (cash and stock).
- Initial Transaction (Feb 15, 2020): $148,722.75 cash and 100,514 IGC shares for 20% of Evolve.
- Remaining Acquisition (Pending): Expected $229,590 cash and 22,040 IGC shares.
- Contingent Consideration: Approximately $300,000 cash and 300,000 IGC shares based on operational goals.
- Earn-out Structure: Up to $5 million total over three years based on revenue and profit targets ($0.9M Year 1, $1.6M Year 2, $2.5M Year 3).
Material Changes and Operational Impact
The company reports significant disruptions due to COVID-19, expected to result in reduced revenue and increased expenses across infrastructure and plant/cannabinoid businesses:
- Infrastructure Business: Revenue affected by staff travel restrictions to Hong Kong and economic disruption there.
- Hemp Processing: Commissioning and certification of equipment in Washington state are delayed because Chinese technicians cannot return to the U.S. due to travel restrictions.
- Supply Chain: Product packaging sourced from China is delayed due to factory closures or minimal staffing, delaying brand launches.
Outlook, Risks, and Management Commentary
Management states the company is "strong and resilient" and views the COVID-19 situation as temporary. Strategic focus remains on FDA trials, intellectual property development, and product commercialization. The company cannot currently estimate the full financial impact of the pandemic.
Key Risks and Contingencies:
- Failure to finalize the Share Purchase Agreement for Evolve I, Inc.
- Failure of Evolve to meet operational, revenue, or profit targets required for earn-out payments.
- Prolonged travel restrictions and economic disruption in China and Hong Kong.
- Regulatory changes regarding hemp-based products and FDA positions.
Investor Verification Checklist
- Verify the final terms and closing status of the Evolve I, Inc. Share Purchase Agreement.
- Monitor the timeline for the return of Chinese technicians to resume equipment commissioning in Washington.
- Assess the extent of supply chain delays for packaging and their impact on specific brand launch dates.
- Review the company's cash reserves to determine if they can sustain increased expenses and delayed revenue.
- Track Evolve I, Inc.'s progress toward the operational goals required to trigger the $300,000 contingent payment.